JPWO2022016129A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022016129A5 JPWO2022016129A5 JP2023503114A JP2023503114A JPWO2022016129A5 JP WO2022016129 A5 JPWO2022016129 A5 JP WO2022016129A5 JP 2023503114 A JP2023503114 A JP 2023503114A JP 2023503114 A JP2023503114 A JP 2023503114A JP WO2022016129 A5 JPWO2022016129 A5 JP WO2022016129A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- polymer
- polymer combination
- network state
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims description 157
- 229920000642 polymer Polymers 0.000 claims description 140
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 23
- 230000002519 immonomodulatory effect Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 238000002271 resection Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- 239000000017 hydrogel Substances 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 14
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000001879 gelation Methods 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- 229960000502 poloxamer Drugs 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000007704 transition Effects 0.000 claims description 6
- 239000004971 Cross linker Substances 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000002269 spontaneous effect Effects 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 229940124613 TLR 7/8 agonist Drugs 0.000 claims description 2
- 230000004721 adaptive immunity Effects 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 239000000701 coagulant Substances 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- 238000002357 laparoscopic surgery Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002324 minimally invasive surgery Methods 0.000 claims description 2
- 210000000066 myeloid cell Anatomy 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 229940044476 poloxamer 407 Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229950010550 resiquimod Drugs 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000002432 robotic surgery Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053488P | 2020-07-17 | 2020-07-17 | |
| US63/053,488 | 2020-07-17 | ||
| US202063108861P | 2020-11-02 | 2020-11-02 | |
| US63/108,861 | 2020-11-02 | ||
| PCT/US2021/042110 WO2022016129A1 (en) | 2020-07-17 | 2021-07-17 | Preparations and compositions comprising polymer combination preparations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534504A JP2023534504A (ja) | 2023-08-09 |
| JPWO2022016129A5 true JPWO2022016129A5 (https=) | 2024-07-17 |
| JP2023534504A5 JP2023534504A5 (https=) | 2024-07-17 |
Family
ID=79555039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503114A Pending JP2023534504A (ja) | 2020-07-17 | 2021-07-17 | ポリマー組み合わせ調製物を含む調製物及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230293427A1 (https=) |
| EP (1) | EP4181857A4 (https=) |
| JP (1) | JP2023534504A (https=) |
| KR (1) | KR20230041032A (https=) |
| CN (1) | CN116133642A (https=) |
| AU (1) | AU2021308083A1 (https=) |
| BR (1) | BR112023000190A2 (https=) |
| CA (1) | CA3187174A1 (https=) |
| IL (1) | IL299806A (https=) |
| WO (1) | WO2022016129A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021329884A1 (en) * | 2020-08-17 | 2023-02-16 | SURGE Therapeutics, Inc. | Immune modulation of myeloid derived suppressive cell function for cancer treatment |
| CN114617903B (zh) * | 2022-03-15 | 2024-05-24 | 中国人民解放军总医院第一医学中心 | 一种用于血浆冻干的组合物及其应用 |
| KR20250030440A (ko) * | 2022-04-29 | 2025-03-05 | 바이오데벡 인코포레이티드 | 생체적합성 접착제 물질 및 사용 방법 |
| IT202300004218A1 (it) * | 2023-03-07 | 2024-09-07 | Delim Cosmetics & Pharma S R L | Composizioni termoreversibili e mucoadesive |
| CN116554949A (zh) * | 2023-05-16 | 2023-08-08 | 广州大学 | 一种润滑油添加剂及其制备方法 |
| CN117619361A (zh) * | 2023-12-09 | 2024-03-01 | 中北大学 | 改性高岭土/包覆型高铁酸钾复合材料及其制备方法 |
| CN120324357B (zh) * | 2025-06-03 | 2025-10-24 | 上海国创医药股份有限公司 | 一种普瑞巴林缓释组合物及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516617A (ja) * | 1995-06-16 | 2002-06-04 | メドロジック グローバル コーポレイション | 反応性ポリマー網状構造体及びその使用法 |
| AU6385796A (en) * | 1995-06-16 | 1997-01-15 | Medlogic Global Corporation | Responsive polymer networks and methods of their use |
| CA2401239A1 (en) * | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| US20060034889A1 (en) * | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| CN101297973B (zh) * | 2008-05-22 | 2010-06-09 | 武汉华纳生物工程有限公司 | 高生物粘附温敏水凝胶及其制备方法和用途 |
| WO2010088924A1 (en) * | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2520279A1 (en) * | 2011-05-02 | 2012-11-07 | TERES S.r.l. | Thermoreversible gel pharamaceutical compositions for odontoiatric use |
| CN103055304A (zh) * | 2013-01-19 | 2013-04-24 | 卓阳 | 一种治疗皮肤溃疡用复方温敏凝胶剂及其制备方法 |
| US9364545B2 (en) * | 2014-06-19 | 2016-06-14 | Taipei Medical University | Thermosensitive injectable hydrogel for drug delivery |
| CN104983722A (zh) * | 2015-07-01 | 2015-10-21 | 苏州吉欧生物科技有限公司 | 一种皮肤祛疤修复喷膜剂的组合物及其制备方法 |
| EP3706718A1 (en) * | 2017-11-07 | 2020-09-16 | Royal College of Surgeons in Ireland | A thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers |
| CN109820816B (zh) * | 2019-02-18 | 2023-04-28 | 江苏拓弘生物科技有限公司 | 温度敏感性生物凝胶制剂及其应用 |
| CN113766929A (zh) * | 2019-05-02 | 2021-12-07 | 斯蒂米特公司 | 癌症治疗 |
| KR102067490B1 (ko) * | 2019-05-21 | 2020-01-20 | 주식회사 티젤바이오 | 서방성 약물전달용 온도상전이 나노 입자/하이드로젤 복합체 |
| US12090205B2 (en) * | 2019-10-28 | 2024-09-17 | Rochal Technologies Llc | Poloxamer compositions with reduced sol-gel transition temperatures and methods of reducing the sol-gel transition temperature of poloxamer compositions |
-
2021
- 2021-07-17 KR KR1020237005332A patent/KR20230041032A/ko active Pending
- 2021-07-17 CN CN202180062155.6A patent/CN116133642A/zh active Pending
- 2021-07-17 EP EP21841706.1A patent/EP4181857A4/en active Pending
- 2021-07-17 US US18/016,096 patent/US20230293427A1/en active Pending
- 2021-07-17 WO PCT/US2021/042110 patent/WO2022016129A1/en not_active Ceased
- 2021-07-17 BR BR112023000190A patent/BR112023000190A2/pt unknown
- 2021-07-17 CA CA3187174A patent/CA3187174A1/en active Pending
- 2021-07-17 JP JP2023503114A patent/JP2023534504A/ja active Pending
- 2021-07-17 IL IL299806A patent/IL299806A/en unknown
- 2021-07-17 AU AU2021308083A patent/AU2021308083A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ryu et al. | Chitosan oral patches inspired by mussel adhesion | |
| CN114369354B (zh) | 用于血管栓塞的可注射水凝胶 | |
| CA2685807C (en) | Polymeric tissue sealant | |
| Fang et al. | Characterization and evaluation of silk protein hydrogels for drug delivery | |
| KR101121480B1 (ko) | 미세다공성 입자를 포함하는 의학적으로 유용한 겔의 형성 및 사용 방법 | |
| ES2383846T3 (es) | Composición farmacéutica que comprende S-nitrosoglutatión y un polisacárido | |
| US12151025B2 (en) | Freeze-dried alginic acid preparation | |
| Elangwe et al. | Evaluation of composition effects on the tissue-adhesive, mechanical and physical properties of physically crosslinked hydrogels based on chitosan and pullulan for wound healing applications | |
| JPWO2022016129A5 (https=) | ||
| JP7830616B2 (ja) | 多糖誘導体の用途 | |
| CN101969922B (zh) | 稳定s-亚硝基谷胱甘肽的方法和用该方法制备的组合物 | |
| CN120267903B (zh) | 一种免疫调控水凝胶及其制备方法与应用 | |
| TWI777517B (zh) | 用於預防沾黏之胺基酸改質的聚合物及其應用 | |
| US20200114047A1 (en) | Liquid-phase composition containing alginic acid or pharmaceutically acceptable salt thereof and colloidal polysaccharide | |
| AU2021394122A1 (en) | Formulations for delivery of bioactive agents | |
| US20210060211A1 (en) | Medical compositions based on crosslinkable hydrophilic polymers | |
| KR102946522B1 (ko) | 석류 추출물 함유 다당류 기반 하이드로젤 주사제 및 지혈제 | |
| EP1150621B1 (en) | Composition for preventing surgical adhesions and tissue damage employing fluorinated polymers | |
| CN116531321A (zh) | 水凝胶复合材料及其制备方法和眼部用药物 | |
| CN113332232B (zh) | 一种含虎杖苷的组合物及其应用 | |
| US20170035861A1 (en) | Flowable hemostatic gel composition and its methods of use | |
| KR20250077320A (ko) | 칸나비디올 필름을 담지한 하이드로겔 복합체 및 이를 포함하는 피부질환 치료용 약학적 조성물 | |
| Bracamonte et al. | Chitosan hydrogels crosslinked with glyoxal as controlled drug release systems | |
| TWI649096B (zh) | 藥物載體及其應用之藥物傳遞系統 | |
| Flores Bracamonte et al. | Chitosan hydrogels crosslinked with glyoxal as controlled drug release systems |